Agrawal Rupesh, Betzler Bjorn Kaijun, Testi Ilaria, Mahajan Sarakshi, Agarwal Aniruddha, Gunasekeran Dinesh Visva, Raje Dhananjay, Aggarwal Kanika, Murthy Somasheila I, Westcott Mark, Chee Soon-Phaik, McCluskey Peter, Ho Su Ling, Teoh Stephen, Cimino Luca, Biswas Jyotirmay, Narain Shishir, Agarwal Manisha, Mahendradas Padmamalini, Khairallah Moncef, Jones Nicholas, Tugal-Tutkun Ilknur, Babu Kalpana, Basu Soumayava, Carreño Ester, Lee Richard, Al-Dhibi Hassan, Bodaghi Bahram, Invernizzi Alessandro, Goldstein Debra A, Barisani-Asenbauer Talin, González-López Julio J, Androudi Sofia, Bansal Reema, Moharana Bruttendu, Esposti Simona Degli, Tasiopoulou Anastasia, Nadarajah Sengal, Agarwal Mamta, Abraham Sharanaya, Vala Ruchi, Singh Ramandeep, Sharma Aman, Sharma Kusum, Zierhut Manfred, Kon Onn Min, Cunningham Emmett T, Kempen John H, Nguyen Quan Dong, Pavesio Carlos, Gupta Vishali
National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore.
Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Ocul Immunol Inflamm. 2020 Sep 30;28(sup1):27-37. doi: 10.1080/09273948.2020.1808226. Epub 2020 Nov 17.
Tubercular intermediate uveitis (TIU) and panuveitis (TBP) are difficult to manage because of limitations in diagnostic tools and lack of evidence-based treatment guidelines. The Collaborative Ocular Tuberculosis Study (COTS) analyzed treatment regimens and therapeutic outcomes in patients with TIU and TBP. Multicentre retrospective analysis. A total of 138 TIU and 309 TBP patients were included. A total of 382 subjects received antitubercular therapy (ATT) (n = 382/447; 85.4%) and 382 received corticosteroids (n = 382/447; 85.4%). Treatment failure was observed in 78 individuals (n = 78/447; 17.4%), occurring less frequently in patients receiving ATT (n = 66/382; 17.2%) compared to those who did not (n = 12/65; 18.5%). The study did not show any statistically significant therapeutic effect of ATT in patients with TIU and TBP. Taking into account the limitations of the retrospective, non-randomized study design, resultant reliance on reported data records, and unequal size of the samples, the current study cannot provide conclusive evidence on the therapeutic benefit of ATT in TIU and TBP.
结核性中间葡萄膜炎(TIU)和全葡萄膜炎(TBP)由于诊断工具的局限性和缺乏循证治疗指南而难以处理。协作性眼部结核病研究(COTS)分析了TIU和TBP患者的治疗方案及治疗结果。多中心回顾性分析。共纳入138例TIU患者和309例TBP患者。共有382名受试者接受了抗结核治疗(ATT)(n = 382/447;85.4%),382名接受了皮质类固醇治疗(n = 382/447;85.4%)。78例患者出现治疗失败(n = 78/447;17.4%),接受ATT治疗的患者(n = 66/382;17.2%)治疗失败的发生率低于未接受ATT治疗的患者(n = 12/65;18.5%)。该研究未显示ATT对TIU和TBP患者有任何统计学上的显著治疗效果。考虑到回顾性、非随机研究设计的局限性、对报告数据记录的依赖以及样本量不均衡,本研究无法提供关于ATT对TIU和TBP治疗益处的确凿证据。